bladder cancer is 60% to 70%. However, in 30% to 50% of the cases, bladder tumors are unresponsive to BCG treatment. In these ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).

Once patients stop responding to BCG, there are few alternatives. One of those alternatives is removal of the bladder which offers the most definitive cancer treatment; however, it is associated ...

There are few treatment options for patients who develop BCG-unresponsive bladder cancer, which raises the risk of the cancer spreading throughout the body. Around 40% of patients don’t respond ...

High-risk, non-muscle-invasive bladder ... invasive cancer within 5 years of diagnosis is highest for this group of patients, and ranges from 25% to 50%, depending on case mix and treatment ...

The treatment landscape for BCG-Unresponsive NMIBC CIS in 2024 For bladder cancer, there are various chemotherapy, thermo-chemotherapy and radiation treatments available. In addition, the U.S ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC ...

10 and bladder-sparing treatment options are still limited. 11,12 “The initial therapy of high-risk, non-muscle invasive bladder cancer with BCG has not advanced in decades. Today’s pivotal ...

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...

On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer ... its ...